Your browser doesn't support javascript.
loading
Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023.
Fabiani, Massimo; Mateo-Urdiales, Alberto; Sacco, Chiara; Rota, Maria Cristina; Fotakis, Emmanouil Alexandros; Petrone, Daniele; Del Manso, Martina; Siddu, Andrea; Stefanelli, Paola; Bella, Antonino; Riccardo, Flavia; Rezza, Giovanni; Palamara, Anna Teresa; Brusaferro, Silvio; Pezzotti, Patrizio.
Afiliação
  • Fabiani M; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Mateo-Urdiales A; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Sacco C; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Rota MC; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Fotakis EA; European Programme on Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control, Stockholm, Sweden.
  • Petrone D; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Del Manso M; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Siddu A; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Stefanelli P; General Directorate of Prevention, Italian Ministry of Health, Rome, Italy.
  • Bella A; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Riccardo F; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Rezza G; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Palamara AT; General Directorate of Prevention, Italian Ministry of Health, Rome, Italy.
  • Brusaferro S; Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
  • Pezzotti P; Office of the President, Istituto Superiore di Sanità, Rome, Italy.
Euro Surveill ; 28(32)2023 08.
Article em En | MEDLINE | ID: mdl-37561053
ABSTRACT
During predominant circulation of SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages (April-June 2023), we found that a second or third booster of Comirnaty bivalent Original/Omicron BA.4-5 mRNA vaccine, versus a first booster received at least 120 days earlier, was effective in preventing severe COVID-19 for more than 6 months post-administration in persons 60 years and above. In view of autumn 2023 vaccination campaigns, use of bivalent Original/Omicron BA.4-5 mRNA vaccines might be warranted until monovalent COVID-19 vaccines targeting Omicron XBB.1 sublineages become available.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Limite: Aged / Humans / Middle aged País/Região como assunto: Europa Idioma: En Revista: Euro Surveill Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Limite: Aged / Humans / Middle aged País/Região como assunto: Europa Idioma: En Revista: Euro Surveill Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália